Impact Investing Conference

ESG Investing Conference

Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability  Yahoo FinanceTwist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability  Yahoo Finance

Impact Investing Forum 2023

London. Dec 05-06, 2023.

Book Now! 

SOUTH SAN FRANCISCO (Calif.), January 31, 2022—-(BUSINESS WIRE)-Twist Bioscience Corporation (NASDAQ : TWST), a company that enables customers to succeed through its offering high-quality synthetic DNA using the silicon platform, today released its first environmental social and governance report (ESG). This report highlights Twist’s commitment to sustainability, social responsibility, and ethics. The full report is available to view at “We are proud of the results of our ESG Report, which reflects our ongoing work since our founding, and that demonstrates our commitment ethical practices, recruitment and developing a diverse workforce worldwide, and fosters a corporate culture where employees feel valued and respected,” Angela Bitting (SVP, corporate affairs, chief ESG officer at Twist Bioscience) said. “Our commitment to writing a future of sustainability starts with the reduced chemical footprint our silicon-based synthetic genome platform and enables customers to more sustainably develop diagnostic tests, therapeutics, agriculture yields and so on,” said Angela Bitting, SVP, corporate affairs and chief ESG officer for Twist Bioscience. As of December 2020, 63% of Twist’s workforce1 was comprised of people of color. Women of color make up 27%. Twist’s global workforce is 39% female. They also have 42% of the executive staff and 30% of its Board of Directors. Twist is committed in ensuring that its workforce is diverse over the long-term. The short-term goal is to increase the percentage of women and racial diversification by 3% by 2022. The company has partnered with California Community Colleges to support diversity in recruitment and inform strong biotech curricula. Twist also offers flexible work arrangements for employees. Twist also offers tuition reimbursement up to $5,250 per annum and internal leadership programs to encourage career growth. Twist encourages employees to get involved in philanthropic efforts and offers 8 hours of paid time off each year for volunteering. Twist’s silicon chips have the same footprint of traditional DNA synthesis methods, but contain millions of nanometer-scale devices. This allows Twist to synthesize more than one million oligos simultaneously, as opposed to the 96-well plates used in other approaches. Twist’s method uses 99.8% less reagent for each gene and produces no excess oligo. This allows Twist to synthesize over one million oligos at once, compared to 96 oligos generated by other approaches. The company works with governments and other DNA synthesis providers to create, promote, and evolve a consistent set o ethical practices. Twist has a comprehensive privacy policy and has been awarded a certificate for the highest level of information security by the International Organization for Standardization (ISO). The company adheres to the same high ethical standards. This includes meticulous record keeping, reporting, and allocating personnel resources. Twist Bioscience Corporation is a leading synthetic biology and genomics company. It has created a disruptive DNA-synthesis platform that will industrialize the engineering and manufacturing of biology. The platform’s core technology is a proprietary technology that pioneers the production of synthetic DNA by “writing” it on a silicon chip. Twist is using its unique technology to produce a wide range of synthetic DNA-based products. This includes synthetic genes, tools for next generation sequencing (NGS), and antibody libraries for drug development and discovery. Twist is also looking for long-term opportunities in digital data storage and biologics drug discovery. Facebook All statements, other than statements of historical fact, are forward-looking statements that reflect the current beliefs and expectations made by management pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act (1996). For information about the risks and uncertainties that could lead to actual results differing from those stated in these forward-looking statement, and risks relating to Twist Bioscience’s business in general, please see Twist Bioscience’s Annual Report Form 10-K filed with Securities and Exchange Commission on November 23, 20,21 and subsequent filings with SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.1 Employee baseView source version on Bioscience
Angela Bitting

SVP, Corporate Affairs

925- 202-6211

Read More


Leave a Reply

Your email address will not be published. Required fields are marked *

ESG Investing Conference

Generated by Feedzy